Other Information.
−Removed: During the three months ended September 30, 2025 , no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended March 31, 2026 , no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: First Amendment to Context License Agreement
+Added: On May 14, 2026, we entered into the Amendment to the Context License Agreement with Context.
+Added: Under the terms of the Amendment, and in full consideration for the amended license rights described below, Context has agreed to pay us:
+Added: (i) $4,500,000, payable within five (5) business days of the effective date of the Amendment, and (ii) $2,000,000, payable by August 1, 2026 (together, the "Amendment Pay-Off Amounts").
+Added: The Amendment Pay-Off Amounts satisfy in full any and all milestone and royalty payment obligations contemplated by the Context License Agreement.
+Added: Among other modifications to the Context License Agreement, under the terms of the Amendment, the license granted to Context under the Context License Agreement is amended to be irrevocable, exclusive, royalty-free, fully paid-up and non-terminable, and any and all diligence obligations with respect to Context are removed.
+Added: The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment filed as Exhibit 10.3 to this Quarterly Report on Form 10-K and incorporated herein by reference.
Exhibit Filing Date
−Removed: Filed/Furnished Herewith
+Added: File/Furnished Herewith
+Added: Agreement and Plan of Merger, dated as of January 30, 2026, by and between BioAtla, Inc.
+Added: and Merger Sub.
+Added: Form of Retention Bonus Agreement between BioAtla, Inc.
+Added: and certain executive officers .
+Added: Retention Bonus Agreement between BioAtla, Inc.
+Added: and Jay Short, effective March 20, 2026
+Added: First Amendment to the License Agreement between BioAtla, Inc.
+Added: and Context Therapeutics Inc., dated as of May 14, 2026
Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Amendment No.
+Added: 1 to Agreement and Plan of Merger, dated as of March 2, 2026, by and between BioAtla, Inc.
+Added: and BA Merger Sub, Inc.
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
−Removed: The following materials from BioAtla’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in iXBRL (inline eXtensible Business Reporting Language):
+Added: The following materials from BioAtla’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in iXBRL (inline eXtensible Business Reporting Language):
(i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations and Comprehensive Loss, (iii) the Condensed Statements of Stockholders’ Equity (iv) the Condensed Statements of Cash Flows, and (v) Notes to Condensed Financial Statements, tagged as blocks of text and including detailed tags.
1 unchanged sentence
Furnished and not filed.
+Added: + Indicates management contract or compensatory plan.
+Added: * Portions of this exhibit have been omitted or redacted in accordance with Item 601(a)(5) or Item 601(b)(10)(iv) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BioAtla, Inc.
−Removed: November 13, 2025
Chief Executive Officer
(Principal Executive Officer)
−Removed: November 13, 2025
−Removed: /s/ Richard A.
+Added: /s/ Christian Vasquez
+Added: Christian Vasquez
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.